![](https://investorshub.advfn.com/uicon/367184.png?cb=1553590500)
Tuesday, September 12, 2023 7:52:09 AM
Source: GlobeNewswire Inc.
Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series).
AUG will pay an upfront payment of $150,000, as well as, for each compound, make a contingent milestone payment of $15,000,000 (for a potential aggregate of $45 million) if the first Food and Drug Administration (FDA) approval is for an indication other than a Rare Pediatric Disease (as defined in the Purchase Agreement), or up to 20% of certain payments, if any, granted to AUG upon any sale of any priority review voucher (PRV) granted to AUG by the FDA, net of any selling costs. Additionally, AUG will assume up to $150,000 of certain liabilities incurred prior to the date of the Purchase Agreement and assume all costs relating to the 800 Series from the date of the Purchase Agreement. The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions, including obtaining certain third-party consents.
“We are excited to announce the transfer of our 800 series programs for the treatment of congenital disorders of glycosylation (CDGs) to AUG. In AUG’s hands, these programs could advance to provide reliable treatments for patients in need. This divestiture also reaffirms Avalo’s unwavering commitment to executing our strategic focus on our immunology assets, which we believe hold the greatest value and potential for our shareholders,” stated Dr. Garry A. Neil, MD, Chief Executive Officer, and Chairman of the Board at Avalo Therapeutics. “This transaction will have an immediate positive impact on our cash flow and reduce the utilization of our internal resources for non-core assets, while also maintaining substantial upside potential for Avalo upon program success.”
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.
LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin ß receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.
For more information about Avalo, please visit www.avalotx.com.
Recent AVTX News
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer • GlobeNewswire Inc. • 06/24/2024 08:01:00 PM
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit • GlobeNewswire Inc. • 06/17/2024 11:30:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/07/2024 11:01:10 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/06/2024 08:03:22 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/03/2024 11:20:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:01:22 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/13/2024 04:38:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 11:33:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:30:59 AM
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/13/2024 11:30:00 AM
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Avalo Reports 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/29/2024 08:01:00 PM
- Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million • GlobeNewswire Inc. • 03/27/2024 08:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 02:13:42 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:02:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:01:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:05:25 PM
- Avalo Therapeutics Announces 1-for-240 Reverse Stock Split • GlobeNewswire Inc. • 12/27/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:01:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:01:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/07/2023 12:02:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 12:01:08 PM
- Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split • GlobeNewswire Inc. • 12/07/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 12:15:21 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM